Drug
Agn 151586
Agn 151586: highest development phase Phase 3, developed by AbbVie. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| AGN-151586 NCT05248867 | Phase 3 | Glabellar Lines |
| AGN-151586 NCT07756580 | Phase 1 | Glabellar Lines |
Latest
No recent events.
Follow Agn 151586 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.